Calquence (acalabrutinib) — United Healthcare
small lymphocytic lymphoma (SLL)
Initial criteria
- Diagnosis of chronic lymphocytic leukemia/small lymphocytic lymphoma
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Calquence therapy
Approval duration
12 months